Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News InVivo Therapeutics Holdings Corp NVIVQ

Healthcare Medical Devices
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCIs). The Company's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. It is intended to promote appositional, or side-by... see more

Recent & Breaking News (OTCPK:NVIVQ)

InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury

Business Wire March 9, 2023

InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

Business Wire October 11, 2022

InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

Business Wire October 7, 2022

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference

Business Wire September 9, 2022

InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

Business Wire July 13, 2022

InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery

Business Wire June 8, 2022

InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study

Business Wire June 2, 2022

InVivo Therapeutics Announces Reverse Stock Split

Business Wire April 14, 2022

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference

Business Wire January 6, 2022

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference

Business Wire September 9, 2021

InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study

Business Wire September 8, 2021

InVivo Therapeutics to Present at Ladenburg Thalmann 2017 Healthcare Conference

Business Wire September 20, 2017

InVivo Therapeutics Announces Publication in Neurosurgery of Lifetime Hospitalization Costs for Thoracic Spinal Cord Injury Patients by Severity Grade

Business Wire September 5, 2017

InVivo Therapeutics Announces Strategic Corporate Restructuring

Business Wire August 28, 2017

InVivo Therapeutics Provides Business Update and Reports 2017 Second Quarter Financial Results

Business Wire August 8, 2017

InVivo Therapeutics to Present at Canaccord Genuity’s 37th Annual Growth Conference

Business Wire August 8, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of InVivo Therapeutics Holding Corp. (NVIV)

PR Newswire July 31, 2017

Mid-Day Market Update: Dynavax Jumps After FDA Approval For Hepatitis B Vaccine; Navigant Shares Drop

Benzinga.com  July 31, 2017

Mid-Morning Market Update: Markets Mostly Higher; Discovery Communications To Acquire Scripps Networks Interactive

Benzinga.com  July 31, 2017

InVivo Therapeutics Announces Updates on the INSPIRE Study

Business Wire July 31, 2017